US Bancorp DE Has $31.04 Million Stock Position in Solventum Corporation $SOLV

US Bancorp DE lowered its stake in Solventum Corporation (NYSE:SOLV) by 5.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 425,140 shares of the company’s stock after selling 25,962 shares during the period. US Bancorp DE owned approximately 0.25% of Solventum worth $31,035,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new stake in Solventum during the second quarter worth about $28,000. Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Solventum during the 2nd quarter worth approximately $31,000. State of Wyoming bought a new position in Solventum in the second quarter valued at approximately $33,000. Finally, MTM Investment Management LLC acquired a new position in Solventum during the second quarter valued at approximately $40,000.

Solventum Stock Performance

Solventum stock opened at $74.12 on Friday. The business has a 50 day moving average of $78.58 and a 200-day moving average of $76.20. The company has a market capitalization of $12.86 billion, a P/E ratio of 8.36, a P/E/G ratio of 7.10 and a beta of 0.35. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 26.99%. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same period in the previous year, the firm posted $1.41 EPS. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum announced that its Board of Directors has approved a stock buyback plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q4 beat — SOLV reported $1.57 EPS and $2.0B revenue, topping estimates with strong demand in surgical/wound-care products, supporting the case for continued organic growth. Read More.
• Positive Sentiment: FY2026 guidance nudged above consensus — management set EPS guidance of $6.40–$6.60, slightly ahead of Street expectations, giving some visibility to full‑year earnings. Read More.
• Positive Sentiment: Analyst bullish signals — KeyCorp raised its price target to $99 (overweight) and BTIG reaffirmed a buy with a $100 target, reflecting upside from better-than-expected results and long-term growth potential. Read More. Read More.
• Neutral Sentiment: Full disclosure for investors — the earnings call transcript and slide deck are available for deeper review of segment performance and cost drivers. Read More.
• Negative Sentiment: Margin pressure — several reports and the company’s commentary highlighted declining margins and cost headwinds despite organic sales growth (organic sales +3.5%, overall sales -3.7% y/y), which is the primary driver of investor concern. Read More.
• Negative Sentiment: Analyst caution — Wells Fargo cut its price target to $83 and moved to an equal‑weight stance, signaling shorter-term skepticism that likely amplified selling after the print. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SOLV. KeyCorp raised their target price on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a report on Friday. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Stifel Nicolaus lifted their target price on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research note on Saturday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.